ReviewThe Korean journal of internal medicine2017
New therapeutic agents in diabetic nephropathy.
Review in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Trial
- Identification of Common Genes Regulated by ER Stress During the Development of Diabetic Nephropathy Based on Human Transcriptome Datasets and an In Vivo Mouse Model.International journal of molecular sciences · 2026Article
- Administration of Trichinella spiralis Antigens Alleviated Diabetic Nephropathy in Diabetic Mice.Acta parasitologica · 2025Article
- Qizhi Jiangtang capsule activates podocyte autophagy in diabetic kidney disease by inhibiting phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome.Renal failure · 2022Article
- Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.The Korean journal of internal medicine · 2022Review
- Piperazine ferulate prevents high-glucose-induced filtration barrier injury of glomerular endothelial cells.Experimental and therapeutic medicine · 2021Article
- Geniposide Improves Diabetic Nephropathy by Enhancing ULK1-Mediated Autophagy and Reducing Oxidative Stress through AMPK Activation.International journal of molecular sciences · 2021Article
- Impact of primary aldosteronism on renal function in patients with type 2 diabetes.Journal of diabetes investigation · 2021Article
- Mesenchymal Stem Cell-Derived Exosomes Carry MicroRNA-125a to Protect Against Diabetic Nephropathy by Targeting Histone Deacetylase 1 and Downregulating Endothelin-1.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Protective effect of exosomes derived from bone marrow mesenchymal stem cells on rats with diabetic nephropathy and its possible mechanism.American journal of translational research · 2021Article
- Rutin ameliorates metabolic acidosis and fibrosis in alloxan induced diabetic nephropathy and cardiomyopathy in experimental rats.Molecular and cellular biochemistry · 2020Article
- Psoralen alleviates high glucose-induced HK-2 cell injury by inhibition of Smad 2 signaling via upregulation of microRNA 874.BMC pharmacology & toxicology · 2020Article
- Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin.BMC nephrology · 2020Article
- Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice.Aging and disease · 2020Article
- Adiponectin for the treatment of diabetic nephropathy.The Korean journal of internal medicine · 2019Review
- Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease.International journal of molecular sciences · 2019Review
- Piperazine ferulate ameliorates the development of diabetic nephropathy by regulating endothelial nitric oxide synthase.Molecular medicine reports · 2019Article
- Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.Journal of cellular and molecular medicine · 2019Article
- Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways.BMC complementary and alternative medicine · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies investigating diabetic nephropathy (DN) have mostly focused on interpreting the pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease onset and progression. Currently, there are few therapeutic drugs for DN, which mainly consist of antihypertensive and antiproteinuric measures that arise from strict renin-angiotensin-aldosterone system inactivation. However, these traditional therapies are suboptimal and there is a clear, unmet need for treatments that offer effective schemes beyond glucose control. The complexity and heterogeneity of the DN entity, along with ambiguous renal endpoints that may deter accurate appraisal of new drug potency, contribute to a worsening of the situation. To address these issues, current research into original therapies to treat DN is focusing on the intrinsic renal pathways that intervene with intracellular signaling of anti-inflammatory, antifibrotic, and metabolic pathways. Mounting evidence in support of the favorable metabolic effects of these novel agents with respect to the renal aspects of DN supports the likelihood of systemic beneficial effects as well. Thus, when translated into clinical use, these novel agents would also address the comorbid factors associated with diabetes, such as obesity and risk of cardiovascular disease. This review will provide a discussion of the promising and effective therapeutic agents for the management of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.